Mutasi Isocitrate Dehydrogenase 1 dan 2 pada Glioma

Ni Putu Sriwidyani

doi:10.24843/JBN.2021.v05.i01.p05

Ni Putu Sriwidyani Departemen Patologi Anatomi Fakultas Kedokteran Universitas Udayana

DOI: https://doi.org/10.24843/JBN.2021.v05.i01.p05

Abstract

Klasifikasi tumor sistem saraf pusat WHO terakhir didasarkan atas histogenesis tumor dan karakteristik molekuler genetik. Perubahan klasifikasi yang paling signifikan terjadi pada tumor glioma difus yang paling signifikan, yaitu katagori tumor secara garis besar berdasarkan status mutasi isocitrate dehydrogenase (IDH) 1 dan 2. Tulisan ini akan membahas tentang IDH1 dan IDH baik normal maupun mutan, hubungan mutasi IDH1 dan IDH2 dengan prognosis pasien, serta bagaimana penentuan status mutasi IDH1 dan IDH2 dalam diagnosis glioma.

Downloads

Download data is not yet available.

References

Louis DN, Perry A, Reifenberger G, dkk. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-20.
2. Lee SC. Diffuse gliomas for nonneuropathologists: The new integrated molecular diagnostics. Arch Pathol Lab Med. 2018;142:804-14.
3. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3:730-41.
4. Maus A, Peters GJ. Glutamate and α-ketoglutarate: key players in glioma metabolism. Amino Acids. 2017;49:21-32.
5. Tommasini-Ghelfi S, Murnan K, Kouri FM, dkk. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Sci Adv.2019;5:eaaw4543.
6. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: New insights and promises for the future. JAMA Neurol. 2014;71:1319-25.
7. Monga V, Jones K, Chang S. Clinical Relevance Of Molecular Markers In Gliomas. Rev Médica Clínica Las Condes. 2017;28:343-51.
8. Yan H, Parsons DW, Jin G, dkk. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73.
9. Huang J, Yu J, Tu L, dkk. Isocitrate dehydrogenase mutations in glioma: From basic discovery to therapeutics development. Front Oncol. 2019;9:506.
10. Olar A, Wani KM, Alfaro-Munoz KD, dkk. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol.2015; 129:585-596
11. Komori T. The 2016 WHO classification of tumours of the central nervous system: The major points of revision. Neurol Med Chir (Tokyo). 2017;57:301-11.